Theralase(R) Closes Private Placement Equity Financing
TORONTO, ON / ACCESSWIRE / September 7, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), is a clinical...
Pharmaceutical
Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services
Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public...
Skye Bioscience Reverse Stock Split to Be Effective on September 8th
San Diego, California--(Newsfile Corp. - September 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary...
HumanFirst Launches New Enterprise Platform to Accelerate Adoption of Precision Measures and Artificial Intelligence in Clinical Research
HumanFirst's new solution aligns AI-powered biomarkers and clinical outcome assessments (COAs) across one platform to drive scientific progress, R&D efficiencies,...
Framework Solutions Expands its Suite of Services with the Strategic Acquisition of Govise, Inc. to Advance its Medical Review Capabilities
DANBURY, Conn. and SANTA ANA, Calif., Sept. 7, 2023 /PRNewswire/ -- Framework Solutions ("Frameworks"), a provider of clinical to commercial...
LSPedia Expands Leadership Capability, Adding Rose Campasano as Vice President of Services
FARMINGTON HILLS, Mich., Sept. 7, 2023 /PRNewswire/ -- LSPedia, a software-as-a-service (SaaS) provider specializing in product traceability solutions for the...
PTC Therapeutics’ 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
- 2023 recipients include patient advocacy organizations in Australia and Brazil - SOUTH PLAINFIELD, N.J., Sept. 7, 2023 /PRNewswire/ --...
Waterdrop Inc. Announces Second Quarter 2023 Unaudited Financial Results
BEIJING, Sept. 7, 2023 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to...
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
Completion of enrollment of study on track by end of 2023Topline data results from interim analysis also on track to...
Jaguar Health’s Executive VP Dr. Karen Brunke Joins BIO’s Rare Disease and Orphan Drugs Committee
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion...
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport...
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase...
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Table 1 Table 1 Chart 1 Chart 1 Chart 2 Chart 2 Table 2 Table 2All study objectives were met,...
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and...
Nexcella to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company engaged...
Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage...
Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently...
CRISPR Therapeutics Announces Leadership Transition
-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023--Samarth Kulkarni, Ph.D., to...
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules
Carlsbad, CA, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic...